Today: 8 February 2026
Subscribe
Browse Category

NYSE:ZTS News 4 November 2025 - 26 December 2025

Zoetis Stock (ZTS) After Hours on Dec. 24, 2025: Price Action, Today’s Headlines, Analyst Forecasts, and What to Watch Before the Next Market Open

Zoetis Stock (ZTS) After Hours on Dec. 24, 2025: Price Action, Today’s Headlines, Analyst Forecasts, and What to Watch Before the Next Market Open

Zoetis Inc. (NYSE: ZTS) wrapped up the Christmas Eve, holiday-shortened session with a solid gain—and then held steady in thin after-hours trading as investors headed into the U.S. market’s Christmas Day shutdown. After the bell on Wednesday, Dec. 24, 2025, ZTS was changing hands around $125.50 in extended trading, essentially flat after-hours, following a session that ended up about +1.6% on the day. MarketBeat+1 Before diving into the headlines and forecasts, one important calendar note: U.S. stock markets are closed Thursday, Dec. 25 (Christmas Day). The next opportunity for U.S. equity trading is Friday, Dec. 26 (a normal session). New
25 December 2025
·
Zoetis Stock (ZTS) News Today: $1.75B Convertible Notes, Accelerated Buybacks, Dividend Raise, and Analyst Forecasts (Dec. 17, 2025)

Zoetis Stock (ZTS) News Today: $1.75B Convertible Notes, Accelerated Buybacks, Dividend Raise, and Analyst Forecasts (Dec. 17, 2025)

Zoetis Inc. (NYSE: ZTS) stock is back in focus on Wednesday, December 17, 2025, as investors weigh a fresh analyst update against a flurry of recent corporate actions—most notably a $1.75 billion convertible notes financing designed to fund substantial share repurchases, plus a dividend increase heading into 2026. MarketScreener+2investor.zoetis.com+2 Zoetis is the world’s largest pure-play animal health company, with a portfolio spanning companion animal and livestock medicines, vaccines, diagnostics, and technology. Business Wire+1 What’s moving Zoetis stock on Dec. 17, 2025? Two themes are dominating today’s conversation around ZTS stock: From a tape-reading standpoint, Zoetis stock has been trading around
17 December 2025
··
Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Company Overview & 2025 Developments Zoetis is the global frontrunner in animal health, offering a diverse portfolio for both companion animals (pets) and farm animals. The company’s products range from vaccines and parasiticides to dermatology treatments and high-tech diagnostics. This breadth has helped Zoetis capture the #1 industry position – in 2023 its $8.5B in sales exceeded the next-largest competitor by over 50%proclinical.comproclinical.com. Zoetis continues to leverage this scale and innovation engine in 2025, focusing on pet care growth while managing challenges in livestock. Recent 2025 highlights: The first half of 2025 saw Zoetis deliver solid growth. In Q1, revenue
4 November 2025
··

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

7 February 2026
Linde plc shares fell 2.5% to $448.24 Friday after reporting Q4 sales up 6% to $8.76 billion and adjusted EPS of $4.20. The company guided 2026 adjusted EPS to $17.40–$17.90, below analyst consensus. JPMorgan downgraded the stock, while Morgan Stanley and UBS raised price targets. Linde repurchased $1.4 billion in shares in Q4 and returned $7.4 billion to shareholders in 2025.
Go toTop